膀胱小細胞癌におけるアベルマブ併用または非併用のルルビネクテジン(レーザー)
膀胱小細胞癌におけるアベルマブ併用または非併用のルルビネクテジンの第II相試験(レーザー)
Background:
Small cell carcinoma of the bladder (SCCB) and other high-grade neuroendocrine tumors (HGNET) of the urinary tract are rare but aggressive cancers. Average survival for people diagnosed with SCCB or HGNET is about 1 year. Lurbinectedin and avelumab are drugs that are approved to treat other cancers. Researchers want to see if these drugs can help people with SCCB or HGNET.
Objective:
To test lurbinectedin with or without avelumab in people with SCCB or HGNET.
Eligibility:
Adults aged 18 years and older with SCBB or HGNET that returned and spread after treatment.
Design:
Participants will be screened. They will have a physical exam. They will have blood tests and imaging scans. They may need to have a new biopsy: A small needle will be used to collect a tissue sample from the tumor.
Both study drugs are given through a tube attached to a needle inserted into a vein. If participants have already received a drug like avelumab they will receive only lurbinectedin. If patients have not been previously treated with a drug like avelumab they will receive both lurbinectedin and avelumab. All participants will receive their treatment once every 3 weeks for up to 10 years. They will also receive other drugs to relieve adverse effects.
Biopsies, blood tests, and imaging scans will be repeated during some study visits. Participants may also have urine tests and tests of their heart function.
Participants may remain in the study as long as the treatment is helping them. If they stop treatment, they will have safety visits 14, 30, and 90 days after their last dose. Additional follow-up visits will continue 5 to 10 years.
調査の概要
詳細な説明
Background:
- Small cell carcinoma of the bladder (SCCB) is a rare, aggressive form of bladder cancer, accounting for less than 1% of all bladder malignancies.
- High grade neuroendocrine tumors (HGNET) of the urinary tract are very rare and include both small cell neuroendocrine carcinomas (SCNEC) and large cell neuroendocrine carcinomas (LCNEC).
- Traditionally regimens drawn from the small cell lung cancer literature (cisplatin and etoposide) are used in the frontline setting, and while initially highly responsive to chemotherapy, responses are generally short lived.
- There is little evidence to guide therapeutic decisions at time of disease progression.
- Lurbinectedin is a selective inhibitor of oncogenic transcription that binds preferentially to guanines located in the GC-rich regulatory areas of DNA gene promoters.
- Lurbinectedin prevents binding of transcription factors to their recognition sequences, inhibiting oncogenic transcription and leading to tumor cell apoptosis.
- Lurbinectedin was recently approved as a second line agent in small cell lung cancer, where it has shown an overall response rate of 35%.
- Immune checkpoint inhibitors (ICIs) have become part of the standard of care for small cell lung cancer, and their use in the community for treatment of SCCB has increased.
- However, ICI use in SCCB is still case reportable in the literature, and no prospective studies have been published to date.
Objective:
-To assess the objective response rate (ORR) of lurbinectedin, either alone or in combination with avelumab, in participants with small cell carcinoma of the bladder (SCCB) or other high grade neuroendocrine tumors (HGNETs) of the urinary tract
Eligibility:
- Age >= 18 years
- Histologically confirmed diagnosis of metastatic SCCB or HGNET of the urinary tract
- Participants must have metastatic disease defined as new or progressive lesions.
- Participants must have at least one measurable site of disease
- Participants must have received, be ineligible, or refused prior platinum/etoposide chemotherapy for SCCB or HGNET of the urinary tract.
Design:
- This is a Phase II, multisite, open label, nonrandomized study with two cohorts.
- All participants will receive lurbinectedin.
- Participants without prior ICI exposure will be eligible to receive concurrent avelumab.
- Treatment will be given in 21-day cycles continuously for up to 10 years or until signs of progression or intolerable side effects.
- Lurbinectedin will be administered intravenously (I.V.) at 3.2mg/m^2 every 21 days.
- Avelumab will be administered I.V. at 800mg every 21 days.
- The accrual ceiling will be set at 35 to allow for a small number of inevaluable participants.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Andrea B Apolo, M.D.
- 電話番号:(301) 480-0536
- メール:apoloab@mail.nih.gov
研究連絡先のバックアップ
- 名前:NCIMO Referral Office
- 電話番号:(888) 624-1937
- メール:ncimo_referrals@mail.nih.gov
研究場所
-
-
Maryland
-
Bethesda、Maryland、アメリカ、20892
- 募集
- National Institutes of Health Clinical Center
-
コンタクト:
- National Cancer Institute Referral Office
- 電話番号:(888) 624-1937
-
コンタクト:
- Lisa Ley
- 電話番号:240-858-3524
- メール:lisa.ley@nih.gov
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
-
INCLUSION CRITERIA:
-
Histologically or cytologically confirmed metastatic small cell carcinoma of the bladder (SCCB) or other high grade neuroendocrine tumors (HGNETs) of the urinary tract (which includes renal pelvis, ureter, and urethra, and excludes neuroendocrine tumors of the prostate). Mixed histologies, with any component including SCCB or HGNETs, are eligible for inclusion.
-
Prior treatment as follows:
- For Cohort 1: Participants must have received prior ICIs (PD-1 or PD-L1) or be ineligible for treatment with ICIs.
- For Cohort 2: Participants must be ICI naive but eligible to receive them.
-
Participants must have metastatic disease defined as new or progressive lesions.
-
Participants must have at least one measurable site of disease, per RECIST 1.1.
-
Participants must have received, be ineligible, or refused prior platinum/etoposide chemotherapy for SCCB or other HGNET of the urinary tract. Platinum ineligibility is defined as a CrCl <30, or two or more of the following: CrCl <50-60, ECOG >=2, hearing loss >= grade 2, peripheral neuropathy >= grade 2, New York Heart Association (NYHA) heart failure class >= class III.
-
Age >=18 years.
-
Eastern Cooperative Oncology Group [ECOG] performance status (PS) <=2 (Karnofsky >=60%).
-
Adequate organ and marrow function as defined below:
-
Absolute neutrophil count (ANC) >=1,500/microliter
-
Platelets >=100,000/ microliter
-
Hemoglobin (Hgb) > 9g/dL (erythrocyte transfusions are allowed to achieve acceptable Hgb)
-
Total bilirubin within normal limits with the following exceptions:
- Participants with tumor involving the liver may have mild to moderate hepatic impairment with total bilirubin <= 1.5 x upper limit of normal (ULN)
- Participants with known Gilbert disease who have serum bilirubin level <= 1.5 x ULN
-
Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) <=1.5 x institutional ULN
---Participants with tumor involving the liver with AST and ALT <= 5.0 x ULN and bilirubin <= 1.5 x ULN may be eligible.
-
Creatinine clearance (CrCl) >= 30 mL/min/1.73 m^2 (glomerular filtration rate [GFR] may be used in place of CrCl. Creatinine clearance or eGFR should be calculated per institutional standard)
-
Creatine phosphokinase (CPK) <= 2.5 x ULN
-
-
Participants with previously treated brain metastases or central nervous system (CNS) metastases are eligible if they have recovered from any acute effects of radiotherapy and not requiring steroids, and any whole brain radiation therapy or any stereotactic radiosurgery was completed at least 2 weeks prior to initiation of therapy.
-
Human immunodeficiency virus (HIV) positive participants are eligible if on stable dose of highly active antiretroviral therapy (HAART), CD4 counts are > 350 cells/mm^3 and viral load is undetectable.
-
Hepatitis B virus (HBV) positive participants are eligible if they have been treated or are on an appropriate course of antivirals at study entry and with planned monitoring and management according to appropriate guidance including prophylaxis.
-
Hepatitis C virus (HCV) positive participants are eligible if:
- they are on active HCV therapy at study entry or are on an appropriate course of antivirals without documented clinically significant impaired liver function test or hematologic abnormalities and with planned monitoring and management according to appropriate labeling, or if they are post-treatment for HCV; or
- they have a negative polymerase chain reaction (PCR).
-
Systemic corticosteroid therapy (defined as >= the equivalent of prednisone 10 mg/day) or other immunosuppressive agents such as azathioprine or cyclosporin must be discontinued at least 1 week prior to treatment initiation for recent short course use (<=14 days) or discontinued at least 4 weeks prior to treatment initiation for long term use (>14 days).
-
Contraception requirements as follows:
Individuals of child-bearing potential (IOCBP) must agree to use a highly effective method of contraception (e.g., intrauterine device [IUD], hormonal, surgical sterilization, abstinence) prior to study entry, for the duration of study participation, and for up to six (6) months after discontinuation of the study drug(s).
- Individuals able to father a child must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of the study treatment and up to six (6) months after the last dose of the study drug(s). We also will recommend individuals able to father a child with IOCBP partners to ask the partners to be on an effective birth control (hormonal, intrauterine device (IUD), surgical sterilization). Individuals able to father a child must not freeze or donate sperm within the same period.
- Nursing participants must be willing to discontinue nursing from study treatment initiation through six (6) weeks after the last dose of the study drug(s).
- Participants must be able to understand and willing to sign a written informed consent document.
EXCLUSION CRITERIA:
-
Prior investigational drug, chemotherapy, immunotherapy or any prior radiotherapy (except for palliative bone directed therapy) within the past 14 days prior to the first drug administration. Additionally, FDA-approved hormonal therapy for the treatment or prevention of other malignancies (e.g., breast cancer, prostate cancer) may be continued where in the opinion of the investigator stopping such therapies may increase the risk of disease progression. Potential drug-drug interactions with the hormonal agent will be assessed by the enrolling investigator prior to enrollment.
-
Participants previously treated with lurbinectedin.
-
History of anaphylactic allergic reactions attributed to compounds of similar chemical or biologic composition to lurbinectedin or avelumab
-
Symptomatic or untreated CNS metastases
-
For Cohort 2: Active autoimmune disease that might deteriorate when receiving avelumab with the exception of:
- Diabetes type I, eczema, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment
- Requirement of hormone replacement with corticosteroids if the steroids are administered only for the purpose of hormonal replacement and at doses <= 10mg of prednisone or equivalent per day
- Requirement of steroids for other conditions through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation)
- Physiologic doses of corticosteroids (<= the equivalent of prednisone 10 mg/day). The use of corticosteroids as premedication for contrast-enhanced studies is allowed prior to treatment initiation and on study.
-
Prior organ transplantation including allogenic stem cell transplantation.
-
Participants who have received or will receive a live vaccine within 30 days prior to the first administration of study intervention. Seasonal flu vaccines that do not contain a live virus and locally authorized/approved COVID-19 vaccines are permitted.
-
Pregnant people as evaluated by a positive serum or urine beta-human chorionic gonadotropin (beta-hCG) test
-
Severe uncontrolled intercurrent illness that would limit compliance with study requirements, evaluated by history, physical exam, and chemistry panel.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm 1
Treatment with lurbinectedin |
Lurbinectedin is administered IV over 1 hour at 3.2 mg/m^2 on day 1 of each 21-day cycle |
|
実験的:Arm 2
Treatment with lurbinectedin and avelumab |
Lurbinectedin is administered IV over 1 hour at 3.2 mg/m^2 on day 1 of each 21-day cycle Avelumab is administered IV at 800 mg over 1 hour on day 1 of each 21-day cycle |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective response rate (ORR)
時間枠:At every restaging (prior to every 3rd cycle) until the end of the treatment
|
Percentage of participants by best overall response (e.g., CR, PR, SD, PD) to therapy |
At every restaging (prior to every 3rd cycle) until the end of the treatment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety of lurbinectedin with or without avelumab
時間枠:From first dose through 90 days after last treatment with the study drug(s)
|
Adverse events (AEs) will be reported by type and grade of toxicity |
From first dose through 90 days after last treatment with the study drug(s)
|
|
Clinical benefit rate (CBR)
時間枠:At every restaging (every 9 weeks) until the end of the study therapy
|
Percentage of participant who have achieved CR, PR, and SD while on treatment. |
At every restaging (every 9 weeks) until the end of the study therapy
|
|
Progression-free survival (PFS)
時間枠:At every restaging (every 9 weeks) until PD
|
Duration of time from start of treatment to time of progression or death, whichever occurs first |
At every restaging (every 9 weeks) until PD
|
|
Overall survival (OS)
時間枠:Day 1 of each cycle, at EoT, at the Safety visits, and every 90 days for up to a total of 10 years after the end of therapy.
|
Time from the start of treatment that participants are still alive. |
Day 1 of each cycle, at EoT, at the Safety visits, and every 90 days for up to a total of 10 years after the end of therapy.
|
|
Duration of response (DoR)
時間枠:At each study visit and at every restaging (every 9 weeks) starting at cycle 3 until PD
|
Time from start of treatment to disease progression or death in participants who achieve CR or PR |
At each study visit and at every restaging (every 9 weeks) starting at cycle 3 until PD
|
協力者と研究者
捜査官
- 主任研究者:Andrea B Apolo, M.D.、National Cancer Institute (NCI)
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 10001523
- 001523-C
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
All collected IPD will be shared@@@@@@
IPD 共有時間枠
This study will comply with the NIH Data Management and Sharing (DMS) Policy, which applies to all new and ongoing NIH-funded research in the IRP, as of January 25, 2023, that is associated with a ZIA, with a clinical protocol that undergoes scientific review and/or will involve genomic data sharing.
IPD 共有アクセス基準
Data from this study may be requested by contacting the PI.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。